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South Africa (SA) faces a rise in non-communicable 
diseases (NCDs) in both rural and urban populations, 
driven by an increase in risk factors such as tobacco 
use, physical inactivity and unhealthy diets.[1] These 
place a heavy burden on public sector primary 
healthcare (PHC) services. A recent cross-sectional survey of reasons 
for consultations in PHC in four SA provinces confirmed that 
management of hypertension was the most common reason for 
attendance, with NCDs accounting for 14% of visits.[2,3]
PHC in the public sector is nurse-led with support from doctors, 
with nurses seeing over 85% of all patients.[2] However, at present 
nurses working at PHC clinics often do not have the necessary skills 
or capacity to deal adequately with NCDs.[1] Chronic diseases and risk 
factors are often undiagnosed and inadequately treated, resulting in 
high levels of poor control and morbidity.[1,4-6]
There is renewed focus on NCD care in SA. However, despite 
the magnitude of the NCD burden, there are few recent studies 
addressing multimorbidity, control and treatment of NCDs in this 
country. In particular, little is known about the multimorbidity of 
depression with other NCDs.
We present an analysis of the clinical characteristics, level of disease 
control, presence of multimorbidity and treatment of patients with 
hypertension, diabetes, chronic respiratory disease and symptoms 
of depression, identified in PHC clinics in the Eden and Overberg 
districts of the Western Cape Province, SA, as part of the Primary 
Care 101 trial described below.
Methods
This study describes the characteristics of patients participating 
in the Primary Care 101 trial at enrolment. The Primary Care 101 
programme comprised a customised clinical practice guideline and 
training programme aimed at assisting healthcare providers, largely 
nurses, with the primary care management of adults. The pragmatic 
cluster randomised controlled trial evaluated the effects of the 
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programme on the quality and outcomes of care for hypertension, 
diabetes, chronic respiratory disease and depression. Clinics were 
randomised either to receive the intervention or not. The main results 
of the trial will be published elsewhere.
The 33 largest clinics in the Eden district that provided NCD 
care, and a convenience sample of five clinics in the neighbouring 
Overberg district, were included in the study. Each clinic had at least 
10 000 attendances per year and was staffed by nurse practitioners, 
doctors, and community health workers who manage clinic patients 
in the communities. These clinics are the main providers of PHC 
for local populations with high levels of unemployment and 
socioeconomic deprivation.
Eligible participants were clinic attenders aged 18 years or older, 
likely to reside in the area for the next year, and able to engage in 
an interviewer-administered questionnaire. Patients attending each 
clinic were interviewed to assess their eligibility for inclusion in 
the hypertension, diabetes, chronic respiratory and/or depression 
groups, until the sample size required for each group was reached. 
For the hypertension and diabetes groups, a self-reported history 
of medication use for these conditions was required. For the 
respiratory group, a self-report of prescription of medications for 
chronic respiratory disease or symptoms of chronic respiratory 
disease (cough or difficult breathing for >2 weeks),[7] and no current 
or recent treatment for tuberculosis, was required. The depression 
group comprised participants with a score of ≥10 on the 10-item 
Center for Epidemiologic Studies Depression Scale (CESD-10).[8] 
Individuals could be included in more than one group. In this article 
‘comorbidity’ refers to two coexisting conditions and ‘multimorbidity’ 
to three or more coexisting conditions.
For trial purposes the sample sizes for each disease group were 
calculated separately, and were 27 participants per clinic for the 
chronic respiratory disease group and 60 per clinic for each of 
the other three groups. These target sample sizes were attained or 
exceeded for all disease groups except the diabetes group, which 
reached 48 participants per clinic.
Fieldworkers invited patients attending the trial clinics to be 
screened for inclusion in the study using a structured questionnaire. 
Eligible patients who provided informed consent were enrolled 
and completed another, baseline, questionnaire. Between March 
and October 2011, 4 904 patients were screened, of whom 4  393 
were enrolled. The questionnaire was available in Afrikaans, 
isiXhosa and English. It included questions relating to demographic 
characteristics, socioeconomic factors, medical history and smoking 
status. Three blood pressure (BP) readings were taken at least 
2 minutes apart with an Omron automatic monitor. The first reading 
was excluded and the values from the second and third readings 
were averaged.[9] Height, weight and waist circumference were 
measured using standardised techniques. Height and weight were 
measured with participants barefoot and wearing light clothing. 
A flexible tape was used to measure waist circumference, 2.5 cm 
above the umbilicus. Haemoglobin A1c (HbA1c) was measured 
only in 20 randomly selected clinics because of cost and logistical 
constraints. Diabetic participants in the 20 clinics were referred to a 
clinic nurse at the end of the interview for an HbA1c test, which was 
processed by the National Health Laboratory Service.
The severity of respiratory disease was assessed with the Symptom 
and Activity domains of the St Georges Respiratory Questionnaire 
(SGRQ)[10] in participants enrolled in the respiratory disease group. 
Scores are expressed as percentages, with 100% representing worst 
and 0% best possible health status. The presence of symptoms 
of depression was assessed with the CESD-10 scale, which was 
administered to all participants enrolled in the study.[8] The items 
were scored from 0 (rarely or none of the time) to 3 (most of the 
time).
Treatment for depression was defined as having received coun-
selling or been referred to psychiatric services within the past year, 
or currently receiving an antidepressant. Counselling was defined as 
a consultation that intended to seek solutions to problems or provide 
emotional support, and not simply give advice on medication use. 
Participants who reported receiving counselling from a mental health 
nurse, clinic counsellor, social worker, psychiatrist or psychologist 
were considered to have received counselling, and those who reported 
receiving counselling from a mental health nurse, psychiatrist or 
psychologist were considered to have been referred to psychiatric 
services.
Chronic medication prescribed to participants at the time of their 
interview for depression, hypertension, diabetes and respiratory dis-
ease was recorded. Fieldworkers photocopied all available prescription 
charts for the year preceding the interview. The trial manager (NF) 
examined the prescription charts of each participant to identify 
medications prescribed at the time of their interview. A data 
capturer entered the prescription data (drug names, doses and 
frequencies) into an access database, and a total daily dose for each 
drug was calculated. Prescription charts were available for 99.3% of 
participants.
Quality control measures included supervision of fieldworkers, 
electronic alert messages for fieldworkers who entered unusually 
high or low values, and regular monitoring of the data to identify 
unusual values or trends. Quality control checks performed on the 
capturing of prescription data included double entry and checking 
all unusually high or low doses and frequencies.
The trial was registered with Current Controlled Trials 
(ISRCTN20283604) and the Office for Human Research Protections 
Database. Ethical approval was obtained from the University of Cape 
Town Human Research Ethics Committee and the Western Cape 
Provincial Department of Health. Participants provided written 
informed consent for their interview and prescription data to be 
collected and analysed. All data were anonymised for analysis, and 
participant identities were revealed only to the fieldworker and a 
limited number of researchers who received and prepared the data 
for analysis.
Results
Thirty-eight clinics were included in the study. The median number 
of nurses per clinic was four. Forty per cent of clinics had daily doctor 
support, the remainder had sessional support from doctors, and 42% 
of clinics had an on-site pharmacy.
A total of 4 393 participants were enrolled into the study, of 
whom 73% were women. The median age was 52 years, and 73% had 
hypertension, 42% diabetes, 26% chronic respiratory disease and 56% 
a CESD-10 score of ≥10 and so could be considered to be at risk of 
depression.
The majority of the participants (84%) were Afrikaans speaking, 
75% were unemployed, 7% had never attended school, and 42% 
had achieved high-school education. Fifty-eight per cent reported 
receiving a social welfare grant, including 44% of participants under 
the age of 60 years. The median income in the month prior to the 
interview date was ZAR1 140, including personal non-grant income 
plus any household grant that benefited the participant, such as a 
disability or child grant.
Although 31% of participants were current smokers, their median 
pack-year history was only 7.5. Twenty-five per cent of participants 
provided a history of cardiovascular disease (heart attack, angina 
or stroke), 11% had a history of tuberculosis (TB), 2% reported 
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being on medication for TB at the time of 
the interview, and 2% reported being on 
antiretroviral drugs.
The NCD-related health characteristics 
of participants in each of the four disease 
groups are presented in Table 1.
In the hypertension group (3 227 parti-
cipants), 59% had a BP ≥140/90 mmHg and 
10% had a BP ≥180/110 mmHg, indicating 
poor control. Their mean body mass index 
(BMI, kg/m2) was 31, 27% were current 
smokers, and 26% reported a history of 
cardiovascular disease. Of the 1 166 parti-
cipants not in the hypertension group, 25% 
had a BP ≥140/90 mmHg and were not on 
medication for hypertension.
The diabetes group comprised 
1 842 participants, of whom 704 had their 
HbA1c measured. The mean HbA1c value 
was 9.1% and 77% had an HbA1c above 
the target of 7%, indicating poor glycaemic 
control. The mean BMI for all participants 
with diabetes was 32, 23% were current 
smokers, and 23% reported a history of 
cardiovascular disease. An elevated BP 
(≥140/80 mmHg)[11] was present in 77%, and 
8% had a BP ≥180/110 mmHg.
The chronic respiratory disease group 
comprised 1 157 participants, of whom 
50% reported being on medication for 
respiratory disease and 50% were identified 
by symptoms alone. Eighteen per cent had a 
previous history of TB and 39% were current 
smokers. Their median pack-year history 
was 7.5. The median symptom and activity 
domain scores of the SGRQ were 60 and 74, 
respectively.
The depression group comprised a total 
of 2 466 participants. Their median CESD-
10 score was 14 (interquartile range (IQR) 
12 - 18).
Of participants with hypertension, 
diabetes, respiratory disease and depression, 
80%, 92%, 88% and 80%, respectively, had at 
least one of the other three conditions, and 
34%, 45%, 53% and 42% had at least two 
other conditions (Fig. 1). Hypertension was 
the commonest comorbidity in participants 
with other categories of chronic disease, 
followed by depression, diabetes and chronic 
respiratory disease. Forty-seven per cent 
of participants in the hypertension group 
also had diabetes, 84% of participants with 
diabetes also had hypertension, 22% of 
participants with hypertension or diabetes 
also had chronic respiratory disease, and 51% 
of participants with hypertension, diabetes 
or respiratory disease had a CESD-10 score 
of ≥10.
Treatment received by participants in the 
hypertension group at the time of their 
interview is presented in Table 2. Four per 
cent of participants in the hypertension 
group had no evidence of having received 
antihypertensive medication, 14% were on 
one antihypertensive agent, and 15% were 
on three or more antihypertensive drugs 
at optimal dosages. Fifty-five per cent of 
participants with hypertension were pre-
scribed aspirin and 34% a statin.
Table 1. Characteristics of study participants
Hypertension group
All participants
(N=3 227)
Systolic BP (mmHg), mean (SD) (n=3 220) 139 (23.6) 
Diastolic BP (mmHg), mean (SD) (n=3 220) 90 (13.2) 
BP ≥140/90 mmHg, n (%) 1 917 (59.4)
BP ≥180/110 mmHg, n (%) 334 (10.4)
BMI (kg/m2), mean (SD) (n=3 066) 31.1 (7.5) 
BMI, proportion obese (BMI ≥30), n (%) 1 628 (50.5)
Waist circumference (cm), mean (SD) (n=3 194) 100.5 (15.6) 
Waist circumference (cm), proportion greater than ideal,* n (%) 2 293 (71.1)
Current smokers, n (%) 885 (27.4)
Pack-year history for current smokers, median (IQR) (n=756) 8 (4.8 - 13.8) 
Cardiovascular disease,† n (%) 849 (26.3)
Diabetes group
All participants
(N=1 842)
HbA1c (%),‡ mean (SD) (n=704) 9.1 (2.5) 
Proportion HbA1c ≥7%, n (%) 544/704 (77.3) 
SBP (mmHg), mean (SD) (n=1 840) 137 (23.2) 
DBP (mmHg), mean (SD) (n=1 840) 88 (12.4) 
BP ≥140/80 mmHg, n (%) 1 414 (76.8)
BP ≥180/110 mmHg, n (%) 139 (7.5)
BMI, mean (SD) (n=1 742) 32.0 (7.3) 
BMI, proportion obese (BMI ≥30), n (%) 1 011 (54.9)
Waist circumference, mean (SD) (n=1 822) 103.6 (14.8) 
Waist circumference, proportion greater than ideal,* n (%) 1 436/1 842 (78.0) 
Current smokers, n (%) 415 (22.5)
Pack-year history for current smokers, median (IQR) (n=353) 8.25 (4.8 - 16.0) 
Cardiovascular disease,† n (%) 423 (23.0)
Chronic respiratory disease group
All participants
(N=1 157)
Self-reported CRD on respiratory medication, n (%) 699 (60.4)
Self-reported CRD symptoms and not on respiratory medication, n (%) 458 (39.6)
SGRQ symptom domain (% maximum weight), median (IQR) (n=833) 59.50 (36.4 - 74.8) 
SGRQ activity domain (% maximum weight), median (IQR) (n=1 054) 73.71 (53.6 - 92.5) 
Current smokers, n (%) 454 (39.2)
Pack-year history for current smokers, median (IQR) 7.8 (4.4 - 13.5)
Previous tuberculosis, n (%) 211 (18.2)
Depression group
All participants
(N=2 466)
CESD-10 score, mean (SD); median (IQR) 15.3 (4.3); 14 (12 - 18)
Current smokers, n (%) 860 (34.9)
Pack-year history for current smokers, median (IQR) (n=754) 7.2 (3.9 - 13.5) 
SD = standard deviation.
*≥88 cm for women, ≥102 cm for men.
†History of heart attack, angina or stroke.
‡HbA1c measured in a preplanned subgroup of 20 randomly selected clinics.
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Treatment received by participants in the 
diabetes group is presented in Table 3. Sixty-
one per cent of participants with diabetes had 
been prescribed an oral hypoglycaemic agent 
(without insulin) and 32% were prescribed 
insulin (with or without oral hypoglycaemic 
agents). Aspirin had been prescribed for 
63% in the diabetes group, and statins 
for 51%. Seven per cent of participants 
with diabetes had had no hypoglycaemic 
agents prescribed. In both the hypertension 
and diabetes groups, we observed higher 
medication use in participants with poorer 
control.
In the respiratory group, 48% of 
participants had been prescribed a 
b2-agonist metered dose inhaler (MDI) or 
nebuliser, 34% an inhaled corticosteroid 
(any dose), 8% an ipratropium bromide 
MDI or nebuliser, and 11% slow-release 
theophylline as maintenance treatment 
(Table 4).
In the depression group, 12% of participants 
had been prescribed a therapeutic dose of 
antidepressant and 10% a subtherapeutic 
dose (<50 mg/d) of amitriptyline or imi-
pramine (Table 5). Twenty-five per cent 
were receiving treatment for depression, 
defined as receiving counselling, referral 
to psychiatric services or being on an 
antidepressant at a therapeutic dose. Forty-
five per cent were not receiving treatment, 
and it could not be established whether the 
remaining 30% were receiving treatment 
for depression, either because prescription 
charts were not available (14 participants) 
or because the participant failed to answer 
the question regarding counselling and 
psychiatric referral (729 participants).
Discussion
This study described the clinical profile, 
disease control, multimorbidity and 
treatment received by patients with the 
target conditions attending PHC clinics in 
two districts in SA. The results indicated 
poor disease control, high levels of multi-
morbidity and unmet treatment needs in the 
public sector in these districts.
These findings confirm previous reports 
of poor control and treatment of NCDs, 
and demonstrate little improvement in 
NCD control since these earlier studies 
were conducted. A study of 1 089 patients 
in 18 community health centres in 1999 
demonstrated poor levels of control of 
hypertension and diabetes in community 
health centres in the Cape Peninsula, with 
67% of hypertensive patients recording a 
BP  ≥140/90 mmHg and a mean HbA1c 
of 8.8% in diabetic patients.[4] A study of 
goldminers in Gauteng Province, SA, in 
2009/2010 found that only 42% of patients 
diagnosed with hypertension received 
antihypertensive medication, while 69% of 
patients on antihypertensive medication 
were poorly controlled.[12] The South African 
Stress and Health Study, a community survey 
of 4 351 adult South Africans between 2002 
and 2004, found that only one-quarter 
of patients with depression, anxiety and 
substance use disorders received treatment. [6] 
Comorbidity of hypertension and diabetes 
was found to be high in a cross-sectional 
study in Cape Town townships in 2008/2009, 
with 21% of participants with hypertension 
also having diabetes, compared with 7% of 
non-hypertensive patients having diabetes. [9] 
The cross-sectional study in the Cape 
Peninsula in 1999 found 31% of participants 
with hypertension to have diabetes and 
64% of participants with diabetes to have 
hypertension.[4] A more recent survey of 
SA PHC found that 18% of patients with 
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Fig. 1. Venn diagram of multimorbidity associated with hypertension, diabetes, chronic respiratory disease 
and depression. (HPT = hypertension; DM = diabetes; CRD = chronic respiratory disease; DEP = depression.)
Table 2. Treatment, hypertension group
Medications prescribed
All participants 
(N=3 227)
n (%)
Controlled 
BP*† (N=1 303) 
n (%)
Uncontrolled 
BP‡† (N=1 917)
n (%) 
Hypertension medications
No hypertension medication 129 (4.0) 80 (62.0) 47 (36.4)
1 hypertension medication 436 (13.5) 207 (47.5) 229 (52.5)
≥2 hypertension medications 2 638 (81.7) 1 003 (38.0) 1 631 (61.8)
 ≥3 antihypertensive 
medications at optimal dosage 
482 (14.9) 140 (29.0) 341 (70.8)
Missing information 24 (0.7)
Aspirin 1 760 (54.5) 711 (40.4) 1 047 (59.5)
Statin 1 093 (33.9) 445 (40.7) 647 (59.2)
*BP <140/90 mmHg.
†Frequencies and row percentages exclude 7 participants with missing BP readings.
‡BP ≥140/90 mmHg.
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hypertension also had diabetes, and 63% 
of patients with diabetes also had hyper-
tension.[3] Our study demonstrated higher 
levels of comorbidity than these studies, 
with 47% of participants with hypertension 
also having diabetes, and 84% of participants 
with diabetes also having hypertension. A 
study of urban SA women demonstrated 
high rates of comorbid psychological distress 
with physical disease,[13] consistent with 
our finding of 51% of participants with 
hypertension, diabetes or chronic respiratory 
disease also having symptoms of depression. 
However, the high rates of multimorbidity 
in our study, particularly in the reporting 
of diabetes in the hypertension group, may 
partly be due to the sampling strategy, as 
explained in ‘Study limitations’ below.
Study limitations and strengths
This study had several limitations. It did 
not consider other potential comorbid 
conditions such as osteoarthritis which 
are likely in such patient populations, so 
multimorbidity and comorbidity were 
probably underestimated. The study was 
not intended to provide estimates of 
the prevalence of NCDs or depression 
symptoms, but its inclusion criteria may 
have influenced the interpretation of results. 
Because the inclusion criteria for each 
condition involved self-reporting, there 
was misclassification; some participants’ 
reported diseases were not confirmed, 
while others were found to be receiving 
medications for a disease that they had not 
reported. For example, of 1 166 participants 
not enrolled in the hypertension group 
(denying receiving medication for this 
diagnosis), 13% had received a prescription 
for antihypertensive medication and 
30% had a BP ≥140/90 mmHg. Further, 
of 3  227 participants who reported being 
on medication for hypertension, 5% 
had no evidence of a prescription for 
hypertension. The inclusion criterion 
for the diabetes group was self-reported 
diabetes medication. Patients with diabetes 
on dietary control alone were therefore 
not included in the study. The study’s 
chronic respiratory disease definition was 
probably more inclusive than usual clinical 
practice and so may have overestimated 
disease prevalence. Spirometry was not 
used to diagnose respiratory disease. We 
did not distinguish between asthma, chronic 
obstructive pulmonary disease or other 
symptomatic chronic lung diseases, and 
severity was not assessed by lung function 
tests. For these reasons, the appropriateness 
of treatments prescribed could not be 
assessed for individual participants. The 
study’s definition of possible depression 
indicates, but does not confirm, clinical 
depression. In addition, the percentage 
receiving counselling or referral is an 
Table 3. Treatment, diabetes group
Medications 
prescribed
All participants 
(N=1 842)
n (%)
Subgroup with 
HbA1c test (N=704)
n (%)
Controlled* 
(N=160)
n (%)
Uncontrolled† 
(N=544)
n (%)
Hypoglycaemic 
medications
 No diabetes 
medications 
119 (6.5) 33 (4.7) 23 (69.7) 10 (30.3)
 Metformin 
and/or 
sulfonylurea 
(but not 
insulin) 
1 126 (61.1) 438 (62.2) 112 (25.6) 326 (74.4)
 Insulin (with/
without oral 
agents) 
588 (31.9) 230 (32.7) 25 (10.9) 205 (89.1)
 Missing 
information
9 (0.5)
Aspirin 1 155 (62.7) 477 (67.8) 101 (21.2) 376 (78.8)
Statin 931 (50.5) 407 (57.8) 82 (20.1) 325 (79.9)
ACE inhibitor 1 215 (66.0) 475 (67.5) 108 (22.7) 367 (77.3)
ACE = angiotensin-converting enzyme.
*HbA1c <7%.
†HbA1c ≥7%.
Table 4. Treatment, chronic respiratory disease group
Medications prescribed 
All participants 
(N=1 157)
n (%)
SGRQ symptom 
domain score
Median (IQR)
SGRQ activity 
domain score
Median (IQR)
No chronic respiratory disease 
medications 
567 (49.0) 52.6 (29.8 - 68.5) 67.2 (47.7 - 85.8)
Selective b2-agonist 558 (48.2) 64.6 (44.9 - 78.9) 79.8 (59.5 - 92.5)
Inhaled corticosteroids (any dose) 388 (33.5) 64.6 (42.8 - 79.3) 80.3 (60.3 - 92.5)
Inhaled corticosteroid (≥800 µg/d) 346 (29.9) 64.9 (41.8 - 80.2) 80.4 (60.3 - 92.5)
Theophylline 121 (10.5) 70.4 (51.8 - 83.0) 79.8 (60.4 - 92.5)
Ipratropium bromide 91 (7.9) 69.7 (52.2 - 81.6) 85.8 (60.4 - 93.2)
Table 5. Treatment, depression group
Medications prescribed or other management
All participants 
(N=2 466)
n (%)
CESD-10 score
Median (IQR)
Antidepressant medications
No antidepressant medications 1 902 (77.1) 14 (12 - 17)
Antidepressant at therapeutic dose 294 (11.9) 19 (14 - 22)
Antidepressant at subtherapeutic dose 250 (10.1) 15 (12 - 19)
Missing information 20 (0.8)
Received counselling in past year 402 (16.3) 15 (12 - 20)
Psychiatric referral in past year 175 (7.1) 17 (13 - 21)
Antidepressant at therapeutic dose or counselling in 
past year or psychiatric referral in past year
614 (24.9) 16 (12 - 20)
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underestimate owing to an error resulting in this question not 
being administered to all participants. Finally, the sampling 
strategy may have led to over-representation of reported 
comorbidities. For the randomised controlled trial we estimated 
that 60 patients were needed per clinic for each disease group 
except for the respiratory group, which required 27 patients per 
clinic. Owing to the high prevalence of hypertension in this clinic 
population, targets were easily met for the hypertension group, 
although it was more difficult to do the same for the diabetes group. 
Fieldworkers were asked to continue recruitment until targets were 
met for all four groups, with the result that targets were exceeded 
for all groups except diabetes, where recruitment fell short (81% 
of target). Since the majority of patients with diabetes also had 
hypertension, extended recruitment of this group may have led to 
an over-representation of the proportion of those with hypertension 
who also had diabetes.
The study had a number of strengths. The sample size was large, 
data were collected for four disease groups, and prescription data 
were collected for 99% of participants. There are few other recent 
studies addressing multimorbidity, control and treatment of NCDs in 
public sector PHC clinics in SA.
Conclusion
The rising prevalence of NCDs is a major challenge facing healthcare 
systems worldwide, with multimorbidity becoming the norm for 
people with chronic diseases. Despite this, health systems tend 
to be configured for individual diseases.[14] The high levels of 
multimorbidity demonstrated in this study stress the need for PHC 
services to provide better-integrated NCD care. Clinicians need to 
consider potential coexistence of, and interactions between, diseases. 
Training of clinicians to manage multimorbidity is essential, and 
should address both appropriateness of prescribing and adherence 
to medication. Management of NCDs and multimorbidity need to be 
addressed at a health systems level and factored into clinical training. 
The Integrated Chronic Disease Management[15] and Primary Care 
101[16] programmes are important current initiatives aimed at 
integrating chronic disease care and addressing multimorbidity. 
After a decade of focusing on scaling up antiretroviral therapy 
programmes, management of NCDs in PHC needs to be prioritised 
and requires similar investment in order to improve outcomes and 
limit the impact on morbidity and mortality. With limited time 
and resources in the PHC setting, careful consideration of how to 
prioritise care is required.
Understanding the causes of poor NCD control will assist in 
prioritising care and resources. Further research is required into the 
development and evaluation of interventions to address the burden 
and unmet treatment needs of NCDs, including mental health.
Funding. This project has been funded in part with Federal funds by the 
United States National Heart, Lung, and Blood Institute, National Institutes 
of Health, Department of Health and Human Services, under Contract 
No. HHSN268200900030C. Funding was also received from United 
Health, USA; the Department of Health of the Provincial Government of 
the Western Cape; the Department of Medicine, University of Cape Town; 
the UK Department for International Development; and the University of 
Cape Town Lung Institute. The study sponsors did not contribute to the 
design of the study, to the collection, analysis and interpretation of data, 
or to the writing of this article or the decision to submit it for publication. 
The researchers were independent from funders and sponsors, and 
researchers involved in the collection, analysis and interpretation of the 
data had access to all the data.
Acknowledgements. The authors thank all clinic nurses, doctors, 
managers, pharmacists and pharmacy assistants at participating study 
facilities; the Department of Health of the Provincial Government of the 
Western Cape; the Eden and Overberg district management; Primary 
Care 101 trainers and fieldworkers; and the National Health Laboratory 
Service.
References
1. Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D. The burden of non-
communicable diseases in South Africa. Lancet 2009;374(9693):934-947. [http://dx.doi.org/10.1016/
S0140-6736(09)61087-4]
2. Mash B, Fairall L, Adejayan O, et al. A morbidity survey of South African primary care. PLoS One 
2012;7(3):e32358. [http://dx.doi.org/10.1371/journal.pone.0032358]
3. Lalkhen H, Mash R. Comorbidity and multimorbidity in non-communicable diseases in South African 
primary healthcare. S Afr Med J 2015;105(2):134-138. [http://dx.doi.org/10.7196/SAMJ.8696]
4. Steyn K, Levitt NS, Patel M, et al. Hypertension and diabetes: Poor care for patients at community 
health centres. S Afr Med J 2008;98(8):618-622.
5. Poyser MA, Nelson H, Ehrlich RI, et al. Socioeconomic deprivation and asthma prevalence and 
severity in young adolescents. Eur Respir J 2002;19(5):892-898. [http://dx.doi.org/10.1183/0903193
6.02.00238402]
6. Williams DR, Herman A, Stein DJ, et al. Twelve-month mental disorders in South Africa: Prevalence, 
service use and demographic correlates in the population-based South African Stress and Health 
Study. Psychol Med 2008;38(2):211-220. [http://dx.doi.org/10.1017/S0033291707001420]
7. English RG, Bateman ED, Zwarenstein MF, et al. Development of a South African Integrated 
Syndromic Respiratory Disease Guideline for Primary Care. Prim Care Respir J 2008;17(3):156-163. 
[http://dx.doi.org/10.3132/pcrj.2008.00044]
8. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: 
Evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J 
Prev Med 1994;10(2):77-84.
9. Peer N, Steyn K, Lombard C, Gwebushe N, Levitt N. A high burden of hypertension in the urban black 
population of Cape Town: The Cardiovascular Risk in Black South Africans (CRIBSA) Study. PLoS 
One 2013;8(11):e78567 [http://dx.doi.org/10.1371/journal.pone.0078567]
10. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med 
1991;85(Suppl B):25-31. [http://dx.doi.org/10.1016/S0954-6111(06)80166-6]
11. Executive Summary: Standards of Medical Care in Diabetes – 2013. Diabetes Care 2013;36(Suppl 
1):S4-S10. [http://dx.doi.org/10.2337/dc13-S004]
12. Maepe LM, Outhoff K. Hypertension in goldminers. S Afr Med J 2012;102(1):30-33.
13. Mendenhall E, Richter LM, Stein A, Norris SA. Psychological and physical co-morbidity among 
urban South African women. PLoS One 2013;8(10):e78803. [http://dx.doi.org/10.1371/journal.
pone.0078803]
14. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health 
care, research, and medical education: A cross-sectional study. Lancet 2012;380(9836):37-43. [http://
dx.doi.org/10.1016/S0140-6736(12)60240-2]
15. Department of Health, Republic of South Africa. Department of Health Annual Report 2011/2012. 
http://www.health.gov.za/ (accessed 27 June 2014).
16. Department of Health, Republic of South Africa. Primary Care 101. http://www.health.gov.za/docs/
Policies/2013/Low_res_PC_101_Guideline_v2.pdf (accessed 4 November 2014).
Accepted 15 June 2015.
